|Mr. Quentin S. Blackford||President, CEO & Director||2.15M||N/A||1979|
|Mr. Brice Bobzien CPA||Chief Financial Officer||685.12k||N/A||1979|
|Dr. Minang P. Turakhia M.D., M.S.||Chief Medical & Scientific Officer and Executive VP of Product Innovation||1M||N/A||1974|
|Mr. Patrick Michael Murphy J.D.||Chief Business & Legal Officer||1.28M||N/A||1979|
|Mr. Douglas J. Devine||Executive Advisor||800k||N/A||1970|
|Mr. Chad M. Patterson||Chief Commercial Officer||771.51k||N/A||1982|
|Mr. Marc Rosenbaum||Senior VP of Finance & Chief Accounting Officer||N/A||N/A||1972|
|Mr. Mark J. Day Ph.D.||Chief Technology Officer||718.76k||1.28M||1971|
|Mr. Daniel G. Wilson||Executive VP of Corporate Development & Investor Relations||670.09k||N/A||1983|
|Ms. Sumi Shrishrimal||Executive VP & Chief Risk Officer||N/A||N/A||1979|
iRhythm Technologies, Inc., a digital healthcare company, provides ambulatory electrocardiogram (ECG) monitoring products for patients at risk for arrhythmias in the United States. It offers Zio service, an ambulatory cardiac monitoring solution that combines a wire-free, patch-based, and wearable biosensor with a cloud-based data analytic platform to help physicians to monitor patients and diagnose arrhythmias. The company's Zio XT and AT monitors, a single-use, wire-free, and wearable patch-based biosensors, records patient's heartbeats and ECG data. It has a development collaboration agreement with Verily Life Sciences LLC to develop various next-generation atrial fibrillation screening, detection, or monitoring products. The company was incorporated in 2006 and is headquartered in San Francisco, California.
iRhythm Technologies, Inc.’s ISS governance QualityScore as of 1 December 2023 is 7. The pillar scores are Audit: 10; Board: 5; Shareholder rights: 6; Compensation: 7.